CSL (CSL) Price & Analysis

Compare

883 Followers

CSL Stock Chart & Stats

AU$147.30

-AU$0.78(-0.27%)

At close: Jan 09 4:00 PM EST

AU$147.30

-AU$0.78(-0.27%)

Day’s Range― - ―

52-Week RangeAU$144.61 - AU$275.79

Previous CloseN/A

Volume375.76K

Average Volume (3M)974.43K

Market Cap

$71.46B

Enterprise ValueAU$62.06B

Total Cash (Recent Filing)$1.15B

Total Debt (Recent Filing)$12.58B

Price to Earnings (P/E)32.6

Beta0.62

Next Earnings

Aug 18, 2026

EPS Estimate

3.97

Next Dividend Ex-DateN/A

Dividend Yield2.58%

Share Statistics

EPS (TTM)5.68

Shares Outstanding485,151,400

10 Day Avg. Volume1,091,561

30 Day Avg. Volume974,433

Financial Highlights & Ratios

PEG Ratio1.90

Price to Book (P/B)3.94

Price to Sales (P/S)4.94

P/FCF Ratio29.97

Enterprise Value/Market Cap0.87

Enterprise Value/Revenue3.95

Enterprise Value/Gross Profit8.13

Enterprise Value/Ebitda12.06

Forecast

1Y Price Target

$220.94

Price Target Upside50.00% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering11

EPS Forecast (FY)6.86

Revenue Forecast (FY)$15.82B

Bulls Say, Bears Say

Bulls Say

Free Cash Flow GenerationA 58% surge in free cash flow indicates materially stronger cash conversion that supports durable capital allocation: funds can be directed to R&D, manufacturing capacity, the announced buyback program, and the Seqirus demerger costs without relying on external financing, improving long-term flexibility.

High And Sustainable MarginsConsistently high gross and operating margins reflect structural advantages in plasma-derived biologics and proprietary therapies. These margins provide durable cushion against pricing pressure and fund reinvestment in pipeline and manufacturing, supporting long-term profitability and competitive defense.

Strong Specialty Franchise GrowthDouble-digit growth in the hemophilia franchise, driven by IDELVION and HEMGENIX uptake, signals durable demand for high-value specialty therapies. This franchise reduces revenue cyclicality tied to vaccines and builds sustainable, higher-margin revenue streams tied to chronic treatment use.

Bears Say

U.S. Pricing And Policy RiskImplementation of IRA Part D reform and potential MFN/pricing changes create structural downside to U.S. reimbursement and pricing power. Given the U.S. market scale for biologics and vaccines, persistent policy shifts can materially compress revenue and margins over the medium term.

Seqirus Revenue SoftnessSeqirus's low growth and soft U.S. seasonal vaccine demand highlight structural volatility from seasonality and tender-driven procurement. This reduces diversification benefits, increases earnings cyclicality, and may limit steady cash contribution until Seqirus's competitive profile is strengthened post-demerger.

Generic Competition In Iron MarketGeneric entrants in the iron therapy market erode pricing and share for Ferinject, signaling a durable product-level threat. Sustained generic pressure can depress segment growth and margins, forcing cost or pricing responses and undermining expected contribution from this portfolio area over the medium term.

CSL News

CSL downgraded to Sector Perform from Outperform at RBC Capital

RBC Capital downgraded CSL (CMXHF) to Sector Perform from Outperform with a price target of A$176, down from...

21d ago

CSL Issues 39,627 New Shares After Conversion of Unquoted Securities

CSL ( ($AU:CSL) ) has shared an announcement. CSL Limited has notified the ASX of the issue of...

12h ago

CSL Updates Market on Progress of On-Market Share Buy-Back

An announcement from CSL ( ($AU:CSL) ) is now available. CSL Limited has provided an updated notification to...

19h ago

CSL Updates Market on Progress of On-Market Share Buy-Back

CSL ( ($AU:CSL) ) has issued an announcement. CSL Limited has provided an update on its ongoing on-market...

2d ago

CSL Issues Daily Update on Ongoing On-Market Share Buy-Back

The latest announcement is out from CSL ( ($AU:CSL) ). CSL Limited has reported an update on its...

6d ago

CSL Updates Market on Progress of On‑Market Share Buy‑Back

CSL ( ($AU:CSL) ) has issued an update. CSL Limited has provided an updated notification to the ASX...

7d ago

CSL Updates Market on Progress of Ongoing On‑Market Share Buy‑Back

An announcement from CSL ( ($AU:CSL) ) is now available. CSL Limited has provided an updated notification on...

8d ago

CSL Updates Market on Progress of On‑Market Share Buy‑Back

CSL ( ($AU:CSL) ) has shared an update. CSL Limited has provided an updated notification on its on‑market...

9d ago

CSL Director Boosts Equity Stake Through Rights Plan Purchase

CSL ( ($AU:CSL) ) has provided an announcement. CSL Limited has disclosed a change in the interests of...

9d ago

CSL Non-Executive Director Increases Indirect Equity Holding Through Rights Plan

CSL ( ($AU:CSL) ) has provided an update. CSL Limited has reported a change in the interests of...

9d ago

CSL Updates Market on Ongoing On‑Market Share Buy‑Back

The latest update is out from CSL ( ($AU:CSL) ). CSL Limited has updated the market on its...

10d ago

CSL upgraded to Outperform from Sector Perform at RBC Capital

RBC Capital upgraded CSL (CMXHF) to Outperform from Sector Perform with a price target of A$230, up from...

1M ago

CSL upgraded to Buy from Hold at Canaccord

Canaccord analyst Shane Storey upgraded CSL (CSLLY) to Buy from Hold with a price target of A$225, down...

4M ago

CSL initiated with an Overweight at Morgan Stanley

Morgan Stanley initiated coverage of CSL (CSLLY) with an Overweight rating and A$313 price target A “solid revenue...

12M ago

CSL FAQ

What was CSL’s price range in the past 12 months?

CSL lowest share price was AU$144.61 and its highest was AU$275.79 in the past 12 months.

What is CSL’s market cap?

CSL’s market cap is $71.46B.

When is CSL’s upcoming earnings report date?

CSL’s upcoming earnings report date is Aug 18, 2026 which is in 167 days.

How were CSL’s earnings last quarter?

CSL released its earnings results on Feb 10, 2026. The company reported AU$5.681 earnings per share for the quarter, missing the consensus estimate of AU$5.837 by -AU$0.155.

Is CSL overvalued?

According to Wall Street analysts CSL’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does CSL pay dividends?

CSL pays a Semiannually dividend of AU$2.451 which represents an annual dividend yield of 2.58%. See more information on CSL dividends here

What is CSL’s EPS estimate?

CSL’s EPS estimate is 3.97.

How many shares outstanding does CSL have?

CSL has 485,151,400 shares outstanding.

What happened to CSL’s price movement after its last earnings report?

CSL reported an EPS of AU$5.681 in its last earnings report, missing expectations of AU$5.837. Following the earnings report the stock price went down -4.639%.

Which hedge fund is a major shareholder of CSL?

Currently, no hedge funds are holding shares in AU:CSL

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

CSL Stock Smart Score

Neutral

Fundamentals

Return on Equity

16.36%

Trailing 12-Months

Asset Growth

3.63%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

CSL

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and CSL Seqirus. The CSL Behring segment offers plasma therapies, such as plasma products and recombinants. This segment also conducts research on plasma and non-plasma therapies; and receives license and royalty from the commercialization of intellectual property. The CSL Seqirus segment manufactures and distributes non-plasma biotherapeutic products; and develops influenza related products. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia.

CSL (CSL) Earnings & Revenues

Historic Earnings Reports

CSL Company Deck

CSL Earnings Call

Q2 2026

0:00 / 0:00

Earnings Call Sentiment|Neutral

CSL demonstrated strong financial growth and strategic initiatives, including successful product launches and plans to streamline operations and enhance R&D efficiency. However, challenges remain in the form of U.S. policy impacts, competitive pressures in the iron market, and a soft performance in the Seqirus segment.View all AU:CSL earnings summaries

CSL Stock 12 Month Forecast

Average Price Target

AU$220.94

▲(50.00% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"146":"AU$146","303":"AU$303","185.25":"AU$185.3","224.5":"AU$224.5","263.75":"AU$263.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":302.6038011,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">AU$302.60</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":220.9429985892,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">AU$220.94</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":174.7096064651595,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">AU$174.71</span>\n  </div></div>","useHTML":true}}],"tickPositions":[146,185.25,224.5,263.75,303],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2025","6":"Sep<br/>2025","9":"Dec<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,147.3,159.24644623846154,171.19289247692308,183.1393387153846,195.08578495384614,207.03223119230768,218.97867743076924,230.92512366923077,242.8715699076923,254.81801614615384,266.7644623846154,278.7109086230769,290.65735486153847,{"y":302.6038011,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,147.3,152.9648460453231,158.62969209064616,164.29453813596925,169.9593841812923,175.6242302266154,181.28907627193846,186.95392231726154,192.6187683625846,198.2836144079077,203.94846045323075,209.61330649855384,215.2781525438769,{"y":220.9429985892,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,147.3,149.40843126655074,151.51686253310146,153.6252937996522,155.73372506620294,157.84215633275366,159.95058759930438,162.05901886585514,164.16745013240586,166.27588139895659,168.3843126655073,170.49274393205806,172.6011751986088,{"y":174.7096064651595,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":255.515,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":248.673,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":248.228,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":244.946,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":235.496,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":261.009,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":207.848,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":198.8,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":178.5,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":183.64,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":172.65,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":177.08,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":147.3,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >